Sugi Predict

Sugi Predict / Compounds / SCHEMBL17815975

SCHEMBL17815975

SCHEMBL17815975

CCC(C(=O)OC(C)(C)C)n1cc(B2OC(C)(C)C(C)(C)O2)cn1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 1/20 0.48
▸ USP30 Q70CQ3 2/20 0.38
▸ AAK1 Q2M2I8 2/20 0.37
▸ DGAT1 O75907 1/20 0.36
▸ PRMT5 O14744 1/20 0.35
▸ WDR77 Q9BQA1 1/20 0.35
▸ UCHL1 P09936 1/20 0.34
▸ BACE1 P56817 1/20 0.33
▸ BACE2 Q9Y5Z0 1/20 0.33
▸ MDM2 Q00987 6/20 0.32
▸ TP53 P04637 5/20 0.32
▸ ACHE P22303 2/20 0.31
▸ JAK2 O60674 1/20 0.31
▸ JAK1 P23458 1/20 0.31
▸ TYK2 P29597 1/20 0.31
▸ JAK3 P52333 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17815873 0.87 FFAR1 (0.45) FFAR1AAK1DGAT1UCHL1ACHE
SCHEMBL17801161 0.85 FFAR1 (0.48) FFAR1USP30AAK1DGAT1PRMT5
SCHEMBL15796448 0.83 FFAR1 (0.48) FFAR1DGAT1UCHL1ACHEJAK2
SCHEMBL17801336 0.83 FFAR1 (0.48) FFAR1DGAT1UCHL1ACHEJAK2
SCHEMBL1712762 0.76 FFAR1 (0.46) FFAR1USP30AAK1DGAT1UCHL1
SCHEMBL2543013 0.75 FFAR1 (0.48) FFAR1USP30AAK1DGAT1PRMT5
SCHEMBL844227 0.75 FFAR1 (0.60) FFAR1USP30AAK1DGAT1PRMT5
SCHEMBL17801114 0.75 FFAR1 (0.51) FFAR1ACHEJAK2JAK1TYK2
SCHEMBL18530443 0.74 FFAR1 (0.44) FFAR1USP30AAK1DGAT1UCHL1
SCHEMBL141413 0.74 FFAR1 (0.52) FFAR1USP30AAK1DGAT1PRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3878451-A1 PHARMACEUTICAL COMPOSITION COMPRISING A JAK-INHIBITING 4,6-SUBSTITUTED-PYRAZOLO[1,5-A]PYRAZINE COMPOUND Array Biopharma Inc. (US) 2021-09-15 — — EP disclosed
EP-3878451-A1 PHARMACEUTICAL COMPOSITION COMPRISING A JAK-INHIBITING 4,6-SUBSTITUTED-PYRAZOLO[1,5-A]PYRAZINE COMPOUND Array Biopharma Inc. (US) 2021-09-15 — — EP disclosed
US-11028093-B2 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors ARRAY BIOPHARMA INC. (US) 2021-06-08 — — US disclosed
US-11028093-B2 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors ARRAY BIOPHARMA INC. (US) 2021-06-08 — — US disclosed
EP-3227297-B1 4,6-SUBSTITUTED-PYRAZOLO[1,5-A]PYRAZINES AS JANUS KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2021-01-20 — — EP disclosed
EP-3227297-B1 4,6-SUBSTITUTED-PYRAZOLO[1,5-A]PYRAZINES AS JANUS KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2021-01-20 — — EP disclosed
US-20200291039-A1 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2020-09-17 — — US disclosed
US-20200291039-A1 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2020-09-17 — — US disclosed
US-10730880-B2 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors ARRAY BIOPHARMA INC. (US) 2020-08-04 — — US disclosed
US-10730880-B2 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors ARRAY BIOPHARMA INC. (US) 2020-08-04 — — US disclosed
US-20190177328-A1 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2019-06-13 — — US disclosed
US-10189845-B2 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-01-29 — — US disclosed
US-10189845-B2 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-01-29 — — US disclosed
US-20170362240-A1 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2017-12-21 — — US disclosed
US-20170362240-A1 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2017-12-21 — — US disclosed
US-20170362240-A1 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2017-12-21 — — US disclosed
WO-2016090285-A1 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2016-06-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200291039-A1 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS JAK1, JAK3, JAK2 FFAR1 1488/4885USP30 2445/4885AAK1 82/4885
US-10730880-B2 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors JAK1, JAK3, JAK2 FFAR1 1488/4885USP30 2445/4885AAK1 82/4885
US-20190177328-A1 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS JAK1, JAK3, JAK2 FFAR1 1488/4885USP30 2445/4885AAK1 82/4885
US-20170362240-A1 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS JAK1, JAK3, JAK2 FFAR1 1488/4885USP30 2445/4885AAK1 82/4885
US-10189845-B2 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors JAK1, JAK3, JAK2 FFAR1 1488/4885USP30 2445/4885AAK1 82/4885
US-11028093-B2 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors JAK1, JAK3, JAK2 FFAR1 1488/4885USP30 2445/4885AAK1 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.